Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015.

Choi SH, Park KS, Kim YJ.

J Infect Chemother. 2019 Mar 15. pii: S1341-321X(18)30360-X. doi: 10.1016/j.jiac.2019.02.013. [Epub ahead of print]

PMID:
30885457
2.

Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.

Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, Cao JL, Sun YP, McLellan JS, Graham BS, Xia NS.

J Virol. 2017 Jul 12;91(15). pii: e00176-17. doi: 10.1128/JVI.00176-17. Print 2017 Aug 1.

3.

Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.

Gilbert BE, Patel N, Lu H, Liu Y, Guebre-Xabier M, Piedra PA, Glenn G, Ellingsworth L, Smith G.

Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30.

PMID:
30389195
4.

An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.

Raghunandan R, Lu H, Zhou B, Xabier MG, Massare MJ, Flyer DC, Fries LF, Smith GE, Glenn GM.

Vaccine. 2014 Nov 12;32(48):6485-92. doi: 10.1016/j.vaccine.2014.09.030. Epub 2014 Sep 28.

5.

Cell fusion assay by expression of respiratory syncytial virus (RSV) fusion protein to analyze the mutation of palivizumab-resistant strains.

Yasui Y, Yamaji Y, Sawada A, Ito T, Nakayama T.

J Virol Methods. 2016 May;231:48-55. doi: 10.1016/j.jviromet.2016.01.003. Epub 2016 Jan 12.

PMID:
26794681
6.

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis.

Oliveira DB, Iwane MK, Prill MM, Weinberg GA, Williams JV, Griffin MR, Szilagyi PG, Edwards KM, Staat MA, Hall CB, Durigon EL, Erdman DD.

J Clin Virol. 2015 Apr;65:26-31. doi: 10.1016/j.jcv.2015.01.016. Epub 2015 Jan 24.

PMID:
25766983
7.

Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.

Hause AM, Henke DM, Avadhanula V, Shaw CA, Tapia LI, Piedra PA.

PLoS One. 2017 Apr 17;12(4):e0175792. doi: 10.1371/journal.pone.0175792. eCollection 2017. Erratum in: PLoS One. 2017 Jun 28;12 (6):e0180623.

9.

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.

DeVincenzo JP, Hall CB, Kimberlin DW, Sánchez PJ, Rodriguez WJ, Jantausch BA, Corey L, Kahn JS, Englund JA, Suzich JA, Palmer-Hill FJ, Branco L, Johnson S, Patel NK, Piazza FM.

J Infect Dis. 2004 Sep 1;190(5):975-8. Epub 2004 Jul 27.

PMID:
15295704
10.

A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.

Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ.

J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. Review.

11.

Detection of respiratory syncytial virus fusion protein variants between 2009 and 2012 in China.

Xia Q, Zhou L, Peng C, Hao R, Ni K, Zang N, Ren L, Deng Y, Xie X, He L, Tian D, Wang L, Huang A, Zhao Y, Zhao X, Fu Z, Tu W, Liu E.

Arch Virol. 2014 May;159(5):1089-98. doi: 10.1007/s00705-013-1870-9. Epub 2013 Dec 3.

PMID:
24297488
12.

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P.

Ir Med J. 2000 Dec;93(9):284.

PMID:
11209917
13.

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.

J Mol Biol. 2007 May 4;368(3):652-65. Epub 2007 Feb 20.

PMID:
17362988
14.
15.

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.

Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006602. doi: 10.1002/14651858.CD006602.pub4. Review.

PMID:
23633336
16.

Neutralizing epitopes of RSV and palivizumab resistance in Japan.

Hashimoto K, Hosoya M.

Fukushima J Med Sci. 2017 Dec 19;63(3):127-134. doi: 10.5387/fms.2017-09. Epub 2017 Sep 1. Review.

17.

Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.

Huang K, Incognito L, Cheng X, Ulbrandt ND, Wu H.

J Virol. 2010 Aug;84(16):8132-40. doi: 10.1128/JVI.02699-09. Epub 2010 Jun 2.

18.

Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.

Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P; Composs Investigators.

Pediatr Infect Dis J. 2002 Jun;21(6):512-8.

PMID:
12182374
19.

Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.

Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S.

Pediatr Pulmonol. 2008 Feb;43(2):169-74.

PMID:
18085710
20.

Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem.

Tripp RA, Power UF, Openshaw PJM, Kauvar LM.

J Virol. 2018 Jan 17;92(3). pii: e01302-17. doi: 10.1128/JVI.01302-17. Print 2018 Feb 1. Review.

Supplemental Content

Support Center